NMRA
Neumora Therapeutics, Inc.
0.5962$
-12.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| – | – | 0.01 | 0.02 | 0.00 | – | 0.03 | |
| – | – | -0.01 | -0.02 | 0.00 | – | -0.03 | |
| – | 0.57 | 1.40 | 0.69 | 0.90 | 1.26 | 1.08 | |
| – | 0.06 | 0.16 | 0.20 | 0.29 | 0.39 | 0.37 | |
| – | 0.63 | 1.56 | 0.89 | 1.18 | 1.65 | 1.45 | |
| – | -0.63 | -1.56 | -0.89 | -1.18 | -1.65 | -1.48 | |
| – | – | – | – | – | – | 0.02 | |
| – | -0.65 | -1.56 | -0.86 | -1.48 | -1.53 | -1.45 | |
| – | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | |
| – | -0.65 | -1.56 | -0.86 | -1.49 | -1.53 | -1.45 | |
| – | -0.63 | -1.56 | -0.86 | -1.48 | -1.52 | -1.43 |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.